39
Participants
Start Date
May 31, 2014
Primary Completion Date
August 31, 2019
Study Completion Date
October 31, 2020
ORAL VINORELBINE
Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.
Hôpital de la TIMONE, Marseille
Hôpital des Enfants, Toulouse
CHU de Bordeaux, Bordeaux
CHRU Arnaud de Villeneuve, Montpellier
CHU de Rennes - Hôpital Sud, Rennes
CHU de Grenoble, Grenoble
CHU d'Angers, Angers
CHU de Reims, Reims
CHU de Nancy, Nancy
Centre Oscar Lambret, Lille
Hôpital Hautepierre, Strasbourg
Centre Léon Bérard, Lyon
Institut Curie, Paris
CHU de Rouen, Rouen
CHU de Limoges, Limoges
Institut Gustave Roussy, Villejuif
Collaborators (1)
National Cancer Institute, France
OTHER_GOV
Pierre Fabre Laboratories
INDUSTRY
Centre Oscar Lambret
OTHER